Report cites FDA’s weaknesses over drugs, devices

WASHINGTON (Reuters) - The U.S. Food and Drug Administration, hampered by increasing globalization and a rise in complex products, may not be able to adequately protect the public’s health, the watchdog arm of Congress said in new findings released on Thursday.

“As a result, the American consumer may not be adequately protected from unsafe and ineffective medical products,” the U.S. Government Accountability Office (GAO) said in adding the FDA to its list of “high-risk” areas of the federal government.

New laws were also challenging the FDA’s ability to ensure the safety of pharmaceuticals, biologic drugs and medical devices, it added. The GAO releases its list at the start of each new Congress to help lawmakers set their priorities.

Numerous other groups, including the Institute of Medicine and various advocacy organizations, have cited the FDA’s challenges in keeping dangerous or ineffective products off the U.S. market.

The agency itself acknowledged it needs to be retooled.

“We need your partnership to reshape the agency and to provide us with the resources and legislative authorities necessary to support our work,” Acting FDA Commissioner Dr Frank Torti said to members of Congress in a statement dated Wednesday.

“For many issues of risk, science does not give us all the answers. When we do not yet know the answers, the FDA will be honest and forthcoming about our uncertainty,” Torti said in his statement, which also addressed consumers, scientists and companies.

Representatives for the agency could not immediately be reached for specific comment on the GAO’s report.

GAO investigators said the FDA needs to have better data on its inspections of facilities in other countries and conduct more inspections.

It also must “more systemically review the claims made in drug advertising and promotional material, and ensure that drug sponsors accurately report clinical trial results,” the GAO said.

The GAO updated list is on its website here

(Reporting by Susan Heavey, editing by Maureen Bavdek)

Source

--------------------------------------------------------------------------------------------
Related Posts:


WASHINGTON (Reuters) - U.S. regulators are asking drugmakers to submit more details about their supply chains under a pilot program announced on Wednesday to help protect patients from fake or tainted medicines from overseas. Companies that voluntarily provide the information can get the products through U.S. border entry points more quickly, Food and Drug Administration officials

Full Post: U.S. seeks details of supply chains for foreign drugs
--------------------------------------------------------------------------------------------

By Lisa Richwine WASHINGTON (Reuters) - U.S. regulators should make sure high-risk medical devices undergo the agency’s toughest review process before they are allowed on the market, a congressional watchdog report said on Thursday. The Food and Drug Administration oversees devices ranging from simple bandages and tongue depressors to the most complex such as pacemakers and heart-valve

Full Post: GAO urges tougher review of some medical devices
--------------------------------------------------------------------------------------------

WASHINGTON (Reuters) - U.S. regulators issued guidelines on Monday that make it easier for drug companies and medical device makers to advise doctors about unapproved uses of their products. The Food and Drug Administration finalized a proposal issued in February 2008 that lets companies distribute medical journal articles describing unapproved uses. By law, manufacturers are prohibited from

Full Post: FDA lets drugmakers advise doctors on unapproved uses
--------------------------------------------------------------------------------------------

WASHINGTON (Reuters) - U.S. regulators need to improve lax oversight of the financial conflicts of doctors who test medicines before they are approved for sale, a government watchdog report said on Monday. The Food and Drug Administration lacks a complete list of doctors conducting research on new medicines and cannot determine which companies have submitted financial

Full Post: Watchdog finds lax U.S. oversight of doctor conflicts
--------------------------------------------------------------------------------------------

NEW YORK (Reuters) - The rise of serious heart risks in drugs that treat chronic conditions has become one of the U.S. Food and Drug Administration’s top worries and is changing how the agency weighs new medicines, a top FDA official said on Tuesday. The agency is thinking about how to weigh such possible side effects

Full Post: Drugs’ heart risk is FDA’s biggest worry: official

Site Navigation

Most Read

Search